All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Interpretation of R2-CHOP in large cell lymphoma

During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Nathan Fowler, MD Anderson Cancer Center, Houston, US, and Chan Cheah, Sir Charles Gairdner Hospital, Nedlands, AU, about the latest trials in malignant lymphomas.

They discussed the results of trials investigating the use of CHOP chemotherapy and lenalidomide in newly diagnosed large cell lymphoma, and how two trials using these regimens had differing outcomes.

Prof Cheah spoke of the differences of these trials, such as the varying dosage of lenalidomide, and the positive and negative results of the two studies.

Interpretation of R2-CHOP in large cell lymphoma